Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of two lansoprazole doses for GERD in term neonates
IRCT20160827029535N9Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lansoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Recovery rate in signs and symptoms of GERD. Started Feb 2022; status: completed.
02
Drugs
lansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on IRCT20160827029535N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160827029535N9.